Cyclerion to Participate at Upcoming September 2020 Investor Conferences

Rhea-AI Summary

Cyclerion Therapeutics (Nasdaq: CYCN), a clinical-stage biopharmaceutical company, announced its participation in several investor conferences in September 2020. Key events include the Citi’s 15th Annual BioPharma Virtual Conference on September 9th, H.C. Wainwright's 22nd Annual Global Investment Conference on September 16th, and the Cantor Virtual Global Healthcare Conference on September 16th and 17th. Additionally, Cyclerion will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21st. Webcasts of presentations will be accessible via Cyclerion's website for 90 days.

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Company management will be participating in several upcoming September 2020 investor conferences:

• Citi’s 15^th Annual BioPharma Virtual Conference on September 9^th
• H.C. Wainwright & Co 22^nd Annual Global Investment Conference on September 16^th at 9:30 a.m. ET
• Cantor Virtual Global Healthcare Conference on September 16^th and a virtual Fireside Chat on September 17^th at 3:20 p.m. ET
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21^st –23^rd on September 21st at 10:50 a.m. ET

A live webcast of the H.C. Wainwright, Cantor, and Oppenheimer presentations can be accessed within the Investors & Media section of the Cyclerion.com website. An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Cyclerion Therapeutics 
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Lead programs include its vascular-targeted olinciguat in Phase 2 development for sickle cell disease and IW-6463, a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv)

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

Investors
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

FAQ

What investor conferences is Cyclerion (CYCN) attending in September 2020?

Cyclerion will participate in the Citi BioPharma Virtual Conference on September 9th, H.C. Wainwright Global Investment Conference on September 16th, Cantor Healthcare Conference on September 16th and 17th, and Oppenheimer Summit from September 21st to 23rd.

Where can I watch Cyclerion's presentations from the September 2020 conferences?

A live webcast of Cyclerion's presentations can be accessed in the Investors & Media section on their website, with replays available for approximately 90 days post-event.

What is Cyclerion Therapeutics focused on developing?

Cyclerion Therapeutics focuses on developing soluble guanylate cyclase stimulators for serious and orphan diseases, with lead programs targeting sickle cell disease and Mitochondrial Encephalomyopathy.